Darolutamide and Radium-223 for Prostate Cancer
Author Information
Author(s): Hagemann Urs B., Schatz Christoph A., Suominen Mari I., Schlicker Andreas, Knuuttila Matias, Wilson Timothy, Alhoniemi Esa, Käkönen Sanna-Maria, Haendler Bernard, Scholz Arne
Primary Institution: Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany
Hypothesis
The combination of darolutamide and radium-223 will exhibit synergistic antitumor efficacy in prostate cancer models.
Conclusion
The study found that darolutamide combined with radium-223 significantly enhances antitumor effects and reduces abnormal bone formation in prostate cancer models.
Supporting Evidence
- The combination treatment showed a suppressive effect on cell proliferation with moderate synergism.
- Darolutamide reduced the number of osteoblasts and osteoclasts in tumor-bearing bone.
- The combination treatment did not affect the uptake of radium-223 into bone tissue.
- Lower PSA concentrations were observed in mice treated with the combination compared to monotherapies.
Takeaway
This study shows that using two medicines together can help fight prostate cancer better than using them alone.
Methodology
The study evaluated the effects of darolutamide and radium-223 in vitro and in an intratibial LNCaP xenograft model.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Male NOD.scid mice, 5–6 weeks old.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website